



Juli 4, 2025

Newsletter

Dear shareholder,

The first half of the year has been marked by strong progress, highlighted by key achievements and full delivery on the objectives outlined in our February 2024 Strategic Plan.

First order from Roche

First and foremost, we are pleased to highlight the long awaited receipt of the first purchase order from Roche for ProNephro AKI™ for the US market. This marks an important strategic milestone in our ambition to establish a commercial platform for kidney diagnostics and drive broad adoption of ProNephro AKI™.

New board composition to boost Nordic profiling

In the years ahead, Bioporto's aims to strengthen its position among institutional investors in the Nordic region. The appointment of Jens Due Olsen as Chairman of the Board marks an important step in that direction.

Jens Due Olsen brings extensive leadership experience from both Danish and international companies across industry, finance and technology. We have strong confidence that his strategic insight and broad network will help guide the company's continued development.

At the same time, Donna Haire has joined as a new board member. Donna Haire has deep expertise in U.S. regulatory matters and will play a key role in the work towards the planned FDA application for the adult use, which we expect to submit by the end of 2026.

A new CEO joins the management team

Carsten Buhl will assume the role of CEO on 1 September. With more than 25 years of experience in the MedTech and life science industry – most recently as President of the Americas at WSAudiology and part of the company's global top management team – Carsten brings strong commercial insight and international perspective. We look forward to leveraging his expertise in the next phase of BioPorto's journey, which will focus on driving sales and growth through the rollout of the NGAL test worldwide.

In addition, we successfully raised DKK 33.5 million in April through a private placement to finance the continued operation and advancement of our activities.

Looking back, we are pleased with the progress made over the past six months and look forward to the remainder of 2025.

Have a great summer

Best regards

Peter M. Eriksen, CEO